LymphomaArchives
Primary diffuse large B-cell lymphoma in the era of targeted therapies: incidence, second primary malignancy and prognosis
Lymphoma 1 min.
To comprehensively illustrate the status of primary diffuse large B-cell lymphoma (DLBCL) in the era of targeted therapies. Data from patients who were newly diagnosed with primary DLBCL from 2000 to 2021 in SEER 17 Registry Database were analyzed. The incidence and occurrence of second primary malignancies...
Predictive accuracy of cytokine pattern with lymphocyte count in infections after chemotherapies for lymphoma
Lymphoma 1 min.
To evaluate whether cytokine profiles combined with lymphocyte count could predict infection risk in lymphoma patients undergoing chemotherapy. Patients & methods...
CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma
Lymphoma 1 min.
CD19-directed chimeric antigen receptor (CAR) T-cell (CAR T) therapy is a well-established treatment for B-cell malignancies, but accessibility, toxicities, lack of persistence, modest anti-tumor activity, restricted trafficking and tumor antigen escape are among its limitations.1 Concern for excessive...
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R
Lymphoma 1 min.
Most patients diagnosed with primary mediastinal B-cell lymphoma (PMBCL) achieve cure following standard-of-care therapy with frontline DA-EPOCH-R (dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, rituximab). However, treatment strategies following relapse after DA-EPOCH-R...
